1. Home
  2. AKBA vs KRUS Comparison

AKBA vs KRUS Comparison

Compare AKBA & KRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$72.24

Market Cap

849.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
KRUS
Founded
2007
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
849.5M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
AKBA
KRUS
Price
$1.43
$72.24
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$6.25
$81.50
AVG Volume (30 Days)
2.9M
378.9K
Earning Date
03-12-2026
01-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$225,071,000.00
$291,762,000.00
Revenue This Year
$52.38
$19.23
Revenue Next Year
$22.45
$20.14
P/E Ratio
N/A
N/A
Revenue Growth
32.49
16.31
52 Week Low
$1.30
$40.03
52 Week High
$4.08
$95.98

Technical Indicators

Market Signals
Indicator
AKBA
KRUS
Relative Strength Index (RSI) 41.75 67.24
Support Level $1.30 $70.48
Resistance Level $1.41 $77.00
Average True Range (ATR) 0.07 4.77
MACD -0.00 0.93
Stochastic Oscillator 37.88 79.19

Price Performance

Historical Comparison
AKBA
KRUS

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

Share on Social Networks: